
Feb 11 (Reuters) - Silo Pharma SILO.O:
SILO PHARMA ANNOUNCES POSITIVE INITIAL PHARMACOKINETIC, SAFETY, AND TOLERABILITY STUDY OF SP-26 FOR CHRONIC PAIN AND FIBROMYALGIA
SILO PHARMA INC - NO SERIOUS SIDE EFFECTS OBSERVED IN SP-26 STUDY
SILO PHARMA INC - FINAL SAFETY AND ABSORPTION DATA EXPECTED IN MARCH 2025
Source text: ID:nGNX7qL6FT
Further company coverage: SILO.O